Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the effect of drug formulation on the extent of the pharmacokinetic interaction between voriconazole and tacrolimus. - TacroVori

Trial Profile

Assessment of the effect of drug formulation on the extent of the pharmacokinetic interaction between voriconazole and tacrolimus. - TacroVori

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs Tacrolimus (Primary) ; Voriconazole (Primary)
  • Indications Allergic conjunctivitis; Allotransplant rejection; Atopic dermatitis; Coronary artery restenosis; Eye-Disorders; Graft-versus-host disease; Interstitial lung diseases; Intestinal transplant rejection; Liver transplant rejection; Lupus nephritis; Myasthenia gravis; Open-angle glaucoma; Psoriasis; Renal transplant rejection; Rheumatoid arthritis; Transplant rejection; Ulcerative colitis
  • Focus Pharmacokinetics
  • Acronyms TacroVori
  • Most Recent Events

    • 01 Oct 2018 Status changed from recruiting to completed.
    • 24 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 11 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top